A: Marie - Licensing Executives Society USA and Canada

The Newsletter of the Licensing Executives Society
Viewpoints
(U.S.A. and Canada), Inc.
Vol. XIX No. 4 November 2012
LES (USA & Canada) President Tanya Moore
Shining The Light On Our Dedicated Team
Tanya Moore began her term as LES (USA & Canada) President by thanking all in attendance
at the 2012 LES (USA & Canada) Annual Meeting in Toronto. Her remarks,
which are stated below, included gratitude to those members retiring from the Board of
Trustees and the LES administrative staff.
I
look forward to the
next year as President
of your Society.
It is a tremendous
opportunity to contribute
to our profession.
I'd like to start by
Tanya Moore
thanking the outgoing
LES (USA & Canada) President Trustees. You've been
seeing their names and
photos on the screen. What you may not know is how dedicated
these folks are to LES. Let me give you a couple of
examples.
Gary Nath joined LES in 1982. He started the Sponsorship
program, through which we now raise half a million
dollars a year to help offset our costs. Over the years, Gary's
firm alone has contributed over a million dollars to LES.
Just think about it … over a million. Another trustee is Phil
Barnett. Phil has been our VP of Education for many years.
He has had a profound impact on our Education curriculum
and CLP program. Phil has talked about and dreamt of a
knowledge management system for a long time, and we are
finally in a position to make his dream a reality. You will be
seeing the fruits of that dream starting next year.
In addition to our tireless volunteers exemplified by these
individuals, I want to thank our executive director Ken
Schoppmann and our fabulous staff. These are folks with
many years of experience in running all aspects of our and
other like organizations. Without them, none of this would
be possible. I look forward to working with each person on
our staff closely throughout next year.
My personal LES story is not unlike many of you here
today. I joined LES in 1998, a year after joining the Corporate
IP Licensing group at IBM. After many years in
software development and OEM Sales, IP Licensing was
new to me, and I started looking for some form of ongoing
education, particularly for an organization focused
on business professionals. I found that most of my IBM
colleagues at the time were members of LES. At first, I
attended some meetings, read the materials and talked
with peers. I later got sucked into the volunteer vortex,
first through the service on the LES Foundation and later
on the LES Board. As one of my LES colleagues recently
said: people join LES for the education, but they stay for
the networking and connections. And this is truer today
than it's ever been.
And now let me say a few words about 2013. The theme for
next year is “Intellectual Property Matters in Every Deal.”
We will focus on all forms of IP in our meetings and make
sure that all members from every industry find something
of interest to listen to and to discuss. We will have three
meetings next year: our IP100 Executive Forum in February
in sunny Phoenix, followed by a general Spring Meeting
in May in Seattle for the first time ever since 1965 and the
Annual Meeting in Philadelphia in late September. We will
work to enhance your online and face-to-face experiences,
infuse more international flavor and focus on exciting topics
to spark conversations.
I look forward to contributing to LES in 2013 and look
forward to seeing many of you at one of the meetings and
in my hometown in the Spring.
Thank you.
What did you miss at
the Annual Meeting?
Pages 8 & 9
Exciting Deals of Distinction,
See Award Winners,
Pages 4-5, 7
Crowdsourcing anyone?
Session breaks new ground,
Page 11
Royalty Rates Revealed:
Workshops help with trends
in all sectors, Page 3

Viewpoints
Officers
President: Tanya Moore
President-Elect: Russell Levine
Past-President: Thomas Filarski
Secretary: Paul A. Roberts
Treasurer: Bob Goldman
Vice-Presidents:
Brian O’Shaughnessy - Regional, USA
Peter M. Ross - Regional, Canada
Art Rose - International
Bill Elkington - Membership
Jeff Whittle - Education
Pamela Demain - Communications
Caroline Rockafellow - Local Chapters
Stasia Ogden - Meeting Programming
Trustees:
Kevin Arst
Rich Baker
Ned Barlas
Cheryl Cejka
Linda Chao
Don Drinkwater
Gary Fedorochko
Bob Held
Panagiota "Betty" Koutsigiannis
Cat Oyler
Hilton Sue
Jack Tupman
Counsel: John Paul
Membership inquiries and contact
changes should be sent to:
E-mail: info@les.org
Web site: www.lesusacanada.org
Editorial inquiries and contributions
should be addressed to:
LES VIEWPOINTS
25125 Detroit Road, #110
Westlake, OH 44145-2500
TEL: 440-871-0571
FAX: 440-871-5218
E-mail: carla@designinterface.com
Editor: Carla J. Blackman
Writers: Linda Corcoran, Lydia Steck
The quarterly newsletter is published by
LES (USA & Canada) and is mailed to all
Society members. Views expressed in articles
are solely those of the respective authors.
Article deadlines for LES Viewpoints:
February 2013: Deadline-Dec. 21, 2012
April 2013: Deadline-Feb. 16, 2013
August 2013: Deadline-July 20, 2013
November 2013: Deadline-Oct. 24, 2013
Copyright © 2012
Licensing Executives Society (U.S.A. and Canada), Inc.
Pamela Demain Receives
2012 Frank Barnes Mentor Award
By Lydia Steck
Merck Executive Director for Corporate
Licensing, Pamela Demain, was honored
with the Frank Barnes Mentor Award during
the LES (USA & Canada) 2012 Annual Meeting
in Toronto.
Now in its 12th year, the Frank Barnes Mentor
Award recognizes individuals who have made significant
contributions to the field of licensing through
professional mentorship.
“Pam was nominated by four LES veterans—two
former Barnes Mentor Award winners and two former
LES Presidents—who have watched her in action,
mentoring LES members and assuming important
leadership roles in the Society, all while working as a
key executive at Merck. Quite a balancing act,” said
Bill Mattson, Chair of the Frank Barnes Award Nominating
Committee. “Pam joins a long and distinguished
line of winners who, like Frank Barnes himself, have
generously shared their time and talents to support their
colleagues and to help advance the mission of LES.”
Joe Dillon presents Pamela Demain
with the Frank Barnes Mentor Award
at the Annual Meeting in Toronto.
Over the years, Ms. Demain has mentored countless LES and other colleagues both formally
and informally. “I believe that mentoring is an important way to give back to LES for all that
it has given me,” she said.
In addition to her contributions of mentorship, Ms. Demain has also served LES as Regional
Vice President, U.S.A, and several years as Vice President for Communications, where she has
overseen a major refocusing and tailoring of LES messages and branding, the launch of the
LES Insights weekly e-newsletter, and the creation of the first LES (USA & Canada) Editorial
Board. She has also been responsible for the development of the first LES Policy Manual. In
addition, she was 2011 Annual Meeting Plenary Chair and as Trustee for Partnering in 2006-
2007, she spearheaded the Power Networking initiative. She has been a member of the Health
Care Committee since 2003, involved in planning for the Health Care Sector at LES (USA &
Canada) meetings and in Viewpoints, and has worked on a number of strategic initiatives with
the Membership and Sponsorship teams. She has been an active LES speaker and attendee at
seasonal, annual and New Jersey Chapter meetings for many years.
As Executive Director for Corporate Licensing at Merck, she is responsible for negotiating
transactions with companies, universities and institutions worldwide. She also heads up relationship
development for licensing. During her more than 30-year career with the company, she
has also worked in Merck’s Global Marketing Division with positions ranging from leading
the Business Information & Research Group to Product Management and Marketing Communications.
Her pharmaceutical career began in the laboratories of Gruppo Lepetit, an Italian
pharmaceutical company, which was then a subsidiary of Dow Chemical Company.
Ms. Demain is a graduate of the University of Massachusetts at Amherst, holds an MBA
in international business from American University in Washington, D.C. and is a Certified
Licensing Professional (CLP).
LES (USA & Canada) Annual Report 2012
Look for the 2012 LES (USA & Canada) Annual Report on the Web
site by going to www.lesusacanada.org.
The document includes reports from the President, President-Elect,
Vice-Presidents of Communications, Education, Member Interests,
Membership, International, and the LES Foundation.
As always, the report includes the financial state of the Society and
biographical sketches of the Board of Trustees.
Printed versions are available by request from the LES (USA &
Canada) office.
2 LES Viewpoints

Royalty Rates Revealed In Annual Meeting Workshops
Global
Life Sciences
Royalty Rates
And Deal Terms
By Lydia Steck
A
panel of members
released its highlyanticipated
2012 Global
BioPharma Royalty Rates and
Deal Terms Survey during a session
at its Annual Meeting.
The new survey builds on
the highly successful surveys
in 2008 and 2010 and was
conducted globally by the LES
(USA & Canada) Life Sciences/
Health Care Sector in coordination
with the LES International
Life Sciences Sector. It targeted
LES and LESI members in the
biotechnology and pharmaceutical
industries, with international
participants representing 17
LESI national societies around
the world.
The final Survey Report, to
be released in November, will
provide exclusive industry-specific
data and detailed analysis
of fixed royalties, tiered royalties,
deal terms and valuation
methods. A robust data set drawing
from this and the previous
surveys provides the opportunity
to individually review deals for
therapeutics, diagnostics, and delivery
innovations. This is highly
valuable information for those
looking for a better understanding
of the market and to enhance
their own deal strategies and
negotiations.
“This new survey represents
an important expansion of the
data set we began with the
2008 and 2010 surveys,” said
Ben Bonifant, Chair of the LES
Global BioPharma Royalty Rates
and Deal Terms Survey. “We
now have enough information to
look at deal trends over time and
to explore important factors affecting
deals for diagnostic and
delivery innovations.”
See Rates, continued on Page 12
Workshop panelists: Robert Held (left),
Ben Bonifant, Jiaqing Lu and Hal Craig.
Comparison Of Royalty Rates, Deal Terms, And Best Practices
Across The CEEM, High Tech And Life Sciences Sectors
By Hal Craig
Drawing on their collective experience and data from LES' Royalty Rate & Deal Terms surveys,
the panelists compared and contrasted licensing across the three sectors and explained differences
and similarities based on the underlying dynamics of each sector and its component industries. This
workshop provided an understanding of the underlying sector value drivers and their potential impact
on licensing transactions.
The panel examined the ideas of "convergence,” a subject of increasing importance as intellectual
property developed for one industry or application finds uses outside its originally intended area. One
of the challenges of convergence is that companies approach licensing and perceive the value of IP
based on the underlying dynamics of their own industry and their perception of less familiar industries.
Interpreting Royalty Rate And Licensing Trends To Protect Your Position
By David Jarczyk
Session attendees learned
about licensing trends
from the past 10 years for
the pharmaceuticals, software,
consumer products, telecommunications,
and chemicals
industries with the goal of
interpreting past trends for future
advantage. The researchers
analyzed data from over
4,000 licenses obtained from
complete agreements filed in
the public domain, and presented
the following key takeaways:
In the pharmaceutical industry
there is a trend to licenseout
manufacturing intangibles.
IP owners often provide exclusive
rights, but generally grant
the licensee non-exclusive
rights in non-primary fields.
Most agreements favor net
sales as a royalty base and incorporate
milestone payments
with well-defined triggers.
In software, over 90% of
agreements involved commercial
licensors. In this industry, the
context of the software license
drives the deal terms. For example,
software licenses in the
telecom industry generally have
higher royalties than those in the
chemicals industry.
In consumer products, licenses
combining manufacturing and
marketing intangibles had the
highest royalty rates, exclusive
rates were significantly higher
than non-exclusive. Analysis
shows that royalty rate increases
faster as patent count increases
from a smaller base; and that
portfolio licensing is an effective
way to reduce royalty stacking.
In telecommunications, there
is a trend to license manufacturing
intangibles and offer minimal
rights to sublicense perhaps to
protect against infringement or
unintended sharing of secrets.
There is a propensity to limit
exclusivity to certain markets,
while allowing non-exclusive
rights in other fields. There is a
preference for royalties based
on net sales.
In the chemicals industry,
industry consolidation and low
production costs will likely lead
to lower than average royalty
rates in the future. Additionally,
licensed know-how bundled with
marketing intangibles tends to
garner the highest royalty rate.
Viewpoints
Future issues of Viewpoints will
be sent to members via an
e-mail link starting in 2013. It
will be in full color and open in
a page-turning software. This
will be the last printed copy
delivered by US Mail.
LES (USA & Canada) wishes
everyone Happy Holidays!
November 2012 3

Sector Spotlight
2012
Deals of
Distinction
Awards
High Technology Sector Winner
AOL, Microsoft & Facebook
The 2012 Deal of Distinction Award for the High Technology
Sector was presented to three of the world’s technology
titans—AOL, Microsoft and Facebook—for a
groundbreaking deal that encompassed a complex series of patent
transactions.
On April 9th, AOL (AOL) sold over 800 of its patents and their
related patent applications to Microsoft (MSFT) and granted
them a non-exclusive license to its retained patent portfolio in
a $1.056 billion cash deal. Soon after, on April 23rd, Facebook
announced it would buy 650 of these patents from Microsoft for
$550 million, leaving the company with 275 of the originally
purchased AOL patents.
The deal is highly advantageous for all involved, but for different
reasons. The transaction allowed AOL to unlock significant
value for its shareholders enabling the company to continue to aggressively
execute on its strategy to create long-term shareholder
value, while maintaining a valuable patent portfolio. Microsoft
and Facebook, meanwhile, received some of the world's earliest
web-related patents—providing important legal protection and
ensuring that those patents did not fall into unfriendly hands. The
acquisition also allowed Facebook to significantly bolster its patent
portfolio at an important time in the company’s development.
“This is a great example of an IP license transaction akin to
some legendary chess moves,” said Bob Held, 2012 High Tech
Sector Deals of Distinction Coordinator. “The strategic benefits
to all three parties far exceeded the monetary component.” ■
By Lydia Steck
A
gigantic patent deal by AOL, Microsoft and Facebook was one
of five extraordinary intellectual property licensing deals that
received LES (USA & Canada) 2012 Deals of Distinction
Awards during the Society's Annual Meeting.
Now in their 8th year, the awards are presented annually to companies
that orchestrate the most outstanding IP-based licensing and business
deals in five industry sectors including: High Technology; Chemicals/
Energy/Environment and Materials; Industry-University-Government
Interface; Life Sciences; and Consumer Products. Here are details on the
winning deals.
Consumer Products Sector Winner
McNeil-PPC Inc. & Insight
Pharmaceuticals LLC
The Consumer Products Sector presented its 2012 Deals
of Distinction Award to McNeil-PPC Inc. and Insight
Pharmaceutical for their asset purchase agreement and
associated licensing.
In August 2011, Insight Pharmaceuticals, a portfolio company
of Swander Pace Capital, acquired the MONISTAT ®
North American brand portfolio from McNEIL-PCC, Inc.
MONISTAT ® , the leading brand in the vaginal antifungal
category, joined Insight Pharmaceuticals’ family of over-thecounter
(OTC) women's health and personal care products,
including brands such as e.p.t ® , Nix ® , Bonnie ® , and Sucrets ® .
The MONISTAT brand was the first prescription product
launched in the vaginal antifungal class in 1974 and established
a category, switching to OTC status in 1991. The acquisition
signals Insight’s increased dedication to the category
of women’s health.
Also, in connection with the transaction, Ontario Teachers’
Pension Plan, through its private equity group, Teachers’
Private Capital, has joined Swander Pace Capital as an equity
investor in Insight Pharmaceuticals.
“We felt this deal was exceptional because it was transformational
for Insight given its size,” said Consumer Product
Sector Deals of Distinction Chair Susan B. Levy. “This was
a multifaceted transaction that included intricate trademark,
patent and know-how licensing, as well as regulatory and
financing complexities.” ■
Bob Held (left), Rich Baker, Annemarie Meike, Tanya Moore of
the LES High Tech Sector present award to Julie Jacobs, Sarah
Harris, Brian Malm and Matt Garber of AOL.
Jim Berwick (left), Insight Pharmaceuticals, and Carlos Forer, Johnson
& Johnson (second from right) accept award from LES Consumer
Products Sector, Susan Levy (left), Robin Sitver and Gail Roth.
4 LES Viewpoints

Industry-University-Government Interface (IUGI)
National Institutes of Health, Univ.
of Illinois–Chicago, Gilead Sciences
& The Medicines Patent Pool
The 2012 Deals of Distinction Award in the Industry-University-Government
Interface Sector (IUGI) was presented to National Institutes of
Health (NIH), University of Illinois at Chicago (UIC), Gilead Sciences
(Gilead), and the Medicines Patent Pool, a newly established initiative of UNI-
TAID, an international organization established for the purchase of drugs against
HIV/AIDS, Malaria, and Tuberculosis.
The Medicines Patent Pool, established by UNITAID in July 2010, is the first
of its kind for HIV medicines. The primary objective of the Medicines Patent
Pool is to improve access to affordable, appropriate HIV medicines in developing
countries through the voluntary licensing of critical intellectual property from
pharmaceutical companies. By streamlining licensing processes for the production
of generic versions of patented HIV medicines for distribution and sale in
the developing world, the Pool aims to serve as a one-stop shop that will speed
up the pace at which newer medicines reach patients, and will help bring prices
down by encouraging competition among multiple producers. It will also spur
innovation, helping to facilitate the development of needed new HIV medicine
formulations for children and of ‘fixed-dose combinations’ that combine several
medicines into one pill, thereby simplifying treatment for patients.
NIH and Gilead are the first licensors to join the Pool and will pave the way
for additional public and private patent holders to help improve the availability of
medicines in developing countries.
The patents licensed by NIH/UIC relate to the protease inhibitor class of HIV
medicines, which are used to treat drug-resistant HIV infection or patients with
high viral loads, as best exemplified to date by the drug darunavir.
The license agreement between Gilead and the Pool in July 2011 includes
patents covering two backbone HIV treatments (disoproxil fumarate and emtricitabine)
together with future rights to patents covering elvitegravir, an investigational
integrase inhibitor; cobicistat, an investigational antiretroviral boosting
agent; and Stribild, which combines tenofovir, emtricitabine, cobicistat and
elitegravir in a once-daily, single-tablet regimen. Stribild has since been approved
by the FDA in August 2012, and was previously referred to as “Quad.”
“The IUGI Sector is pleased to recognize this model partnership between the
NIH, UIC, Gilead Sciences and the Medicines Pool. This is truly an innovative
endeavor in facilitating access to HIV treatment in developing countries.
It showcases the success of public-private partnerships to improve availability
of medicine,” said IUGI Sector Chair Ida Shum. “Many thanks to our Deals of
Distinction Committee members: Vasu Pestonjamasp, Thierry Musy-Verdel and
John McEntire.” ■
Chemicals, Energy,
Environment and Materials
(CEEM) Sector Winner
Sabine Pass Liquefaction,
LLC & ConocoPhillips
Company
The Chemicals, Energy, Environment
and Materials (CEEM) Sector's 2012
Deals of Distinction Award was presented
to Sabine Pass Liquefaction and ConocoPhillips.
The award was in recognition of a
technology agreement that will allow for the
practice of ConocoPhillips Optimized Cascade
® Process for natural gas liquefaction in
two liquefaction trains. The trains will have a
combined capacity of nominal 9.0 mtpa and
will be located in Cameron Parish, Louisiana
as part of the Sabine Pass LNG Project.
“This is the first world-scale natural gas
liquefaction facility to be built in North
America in more than 40 years,” said CEEM
Deals of Distinction Chair Anne Culotta.
“The two companies worked closely to ensure
that the proprietary aspect of the technology
was maintained while successfully obtaining
the necessary government approvals and project
financing for this $4.5-$5 billion dollar
natural gas export project.”
The technology is premised on the process
used in the only other world-scale natural gas
liquefaction plant in North America, the Kenai
Alaska LNG facility, which was designed
by Phillips Petroleum Company (now ConocoPhillips
Company) and has been in operation
since 1969. The technology is currently
being used in 10 liquefaction trains located in
Alaska, Trinidad, Egypt, Equatorial Guinea,
Australia and Angola. An additional 10 trains
are under construction in the United States
and Australia. ■
Claire Driscoll (left), (NIH) National Institutes of Health; Chan Park,
Medicines Patent Pool; Gregg Alton, Gilead Sciences, Inc.; and Chair of
the IUGI Sector, Ida Shum, Lawrence Livermore National Laboratory.
Anne Culotta, LES CEEM Sector (left) and
Gary Haag, accepting for ConocoPhillips
and Sabine Pass Liquefaction.
See Page 7 for the Life Sciences Deal of Distinction. November 2012 5

Foundation FOCUS By Lydia Steck
Past Competition Volunteers Tell It Like It Is!
The 2013 Graduate Student Business Plan Competition
officially kicked off on November 12th, and as student
registrations continue to roll in, the LES Foundation
invites you to share your knowledge and expertise by volunteering
this year.
Worried about the commitment? Don’t be. Here is what past
Competition volunteers had to say about their experiences:
How will you choose to contribute
to the success of Competition 2013?
• Raise Awareness by encouraging
participation from a graduate
school program in your area.
• Mentor a team by phone. Provide
expertise and input for a participating
team.
www.lesfoundation.org
• Judge a handful of business plans in
your area of expertise.
• Teach an IP & Licensing Basics
Course for teams in your area.
• Donate cash or an in-kind prize
for the Competition.
• Contact us at bplan@lesfoundation.
org if you’d like to get involved!
Judge and Mentor
Ada Nielsen,
Past President,
LES (USA & Canada)
“The Business Plan Competition
puts us in the
lead for attracting some
of the brightest and the
best around the world
to learn the language and
the importance of inventions,
IP, and licensing in
creating value in business
enterprises. This event
really energizes us to
work with local teams
of graduate students and
professors and to interact
with the participants at
the Finals."
Judge and Mentor
Les Goff, Former
LES Foundation
Board Member and
Chair of the Competition
Mentor Program
“I really enjoy mentoring
the teams. But
I have to admit, it’s
a little self-serving
because the process
offers me an opportunity
to meet some of
the best students from
top graduate programs
across the globe and
to see fresh ideas and
leading entrepreneurship
trends.”
2012 Final Round Judge
Cheryl Cejka, LES (USA
& Canada) Trustee
“It was really fun to do.
We had six teams in
the final round and they
were all excellent. I have
judged a lot of business
plan competitions and this
was definitely the highest
caliber competition I have
been involved with. It was
also great because we
had the opportunity to
interact with the individual
students and teams and to
provide them with mentoring
and connections to
help get them going onto
their next level.”
2011 On-site Mentor
Karen Sinclair,
Past President of
LES Australia and
New Zealand
“Being a mentor
brought a new dimension
to the meeting.
Now there was also
the enthusiasm and
adrenalin of the team
to ride, the excitement
of the Competition, and
involvement in a process,
which provoked
thoughts about how I
‘give back’ and pass my
knowledge along to the
next generation.”
2011 Final Round
Judge
Mark Wilson,
Past President of
LES Britain and
Ireland
“The Competition
was a very positive
experience. I
enjoyed interacting
with the participants.
Here was an
opportunity for the
students to talk to
senior industrialists
and to discuss
what’s really
required to build
viable businesses.”
The LES Foundation Board gathers in Toronto:
Patrick O’Reilley (back left), Arthur Rose, Thomas
Britven, Rob McInnes; (front left) Linda Chao,
Annemarie Meike and Laura O'Shea.
Key Dates:
2013 LES Foundation Competition
Nov. 12, 2012–Jan 31, 2013 IP Mentoring Support Registration
Feb. 1–Feb 28, 2013
Business Plan Submission
March 10–16, 2013 First Round Judging Phase 1
March 18–24, 2013
First Round Judging Phase II
April 7–10, 2013
Finalist Announcement, 2013 LESI Annual
Conference, Rio de Janeiro
May 13 & 14, 2013
Final Round and IP & Licensing Basics
May 14–16, 2013
LES (USA & Canada) Spring Meeting, Seattle
LES Foundation Board 2012-2013
President – Tom Britven
Secretary – Peter Ross
Treasurer – Michael Samardzija
(assisted by Jeremy Hamblen)
Vice Presidents
• Patrick O’Reilley, Europe
Outreach
• Annemarie Meike – Chair of
2013 Competition
• Linda Chao – Competition
Advisor, High Tech Outreach
• Mark Nawacki – Mentoring Program, Life
Sciences Outreach
• Peter Ross – LES USA/Canada Outreach,
Americas/Canada Outreach
• Rob McInnes – LESI International
Outreach, Asia/Australia Outreach
• Tom Filarski – Past LES President Advisor
Advisors
• Lydia Steck – Communications
• Les Goff – Mentoring Program
6 LES Viewpoints

CLP Website
Gets New Look
And Layout
By Cynthia Allen
The CLP Website has a new
look and layout to help exam
candidates and current certificants
access the information they
need to navigate the certification
and recertification processes. Visit
the new website at www.licensingcertification.org
and check out
these features:
• Access the most popular links
on the Web site from any page
on the site using the “Top Links”
navigation bar. The most popular
links on the CLP site are the eligibility requirements, candidate handbook,
practice test, application and FAQs.
• Review the News section features the certificant-only newsletter, CLP
Connection, and announcements about the CLP program and certificants.
CLP Connection is printed two times annually. The next issue comes in
December via email to all current certificants.
• Download helpful resources to help you promote your achievement
including a sample press release, marketing tips, and guidelines for using
the CLP credential.
• Download the CLP practice test if you are considering taking the CLP
exam. The practice test includes 50 multiple-choice questions that are representative
of the questions on the CLP certification exam.
Remember the CLP exam will be offered again in April 2013. Applicants
receive two testing opportunities within a 13-month window. Visit the new
CLP Website at www.licensingcertification.org to learn more about the CLP
certification process. ■
CLP Elects New Governors And Officers
The CLP Board of Governors has elected new Governors and
Officers for 2012–2013. They met in Toronto to discuss plans
for the upcoming year.
Deals of Distinction TM
Life Sciences Sector Winner
Eli Lilly &
Boehringer Ingelheim
Strategic Alliance
The global population of people with diabetes
is expected to explode from the current level
of 366 million to 600 million by 2030. Never
has there been a more urgent need for new solutions
to address the diverse requirements of people with
diabetes. The Life Science Sector honored Eli Lilly
and Company (Lilly) and Boehringer Ingelheim with
the 2012 Deals of Distinction Award for their efforts
to combine their substantial scientific expertise and
business capabilities to deliver solutions by jointly
developing and commercializing four new promising
medicines in diabetes care by 2016. Through
the alliance, Lilly is building its presence in the
fast-growing market for oral agents to treat diabetes,
while Boehringer Ingelheim will gain access to the
insulin market.
The deal is unique not only because of its value, but
also because of its creative structure, which merges
pipelines from two companies allowing both to
maximize their development and commercialization
resources. The alliance molecules include two oral
treatments, the DPP-4 inhibitor Linagliptin and the
SGLT2 inhibitor Empagliflozin, contributed by Boehringer
Ingelheim and two insulin basal analogues,
LY2605541 and LY2963016, contributed by Lilly.
“The Boehringer Ingelheim-Lilly deal structure
creates a remarkably impressive strategic alliance
with bold risk-sharing and outstanding upside
potential unique to the industry. The alliance has
been engineered to boost both companies’ presence
in a highly competitive market while meeting the
complex needs of a large and growing global patient
population,” said Life Science Sector Chair Joseph
Dillon. The deal also makes both companies more efficient
in the competitive diabetes-care marketplace. ■
The CLP Board: back row (left to right) - Cynthia Allen; Mike Lee, Vice-
President; Paul Stewart, President; Ernie Posner; Laurent Mieville
Front Row (left to right) - Robin Rasor, Secretary; Lesley Millar; Sue Patow;
and François Painchaud, Treasurer.
Jack Tupman (right), Eli Lilly, accepts the award from
Life Sciences Sector Chair Joe Dillon.
November 2012 7

Connecting And Collaborating With A Canadian F
By Linda Corcoran
When Canadian Mountie (Meeting Chair Tim Lowman)
and Her Majesty The Queen (Susan Peacock) took
center stage in Toronto, more than 800 meeting attendees
roared with expectations that this was going to be a meeting
to remember – Canadian style, eh! The LES (USA & Canada)
2012 Annual Meeting proved to be a success on every level, from
groundbreaking speakers to engaging workshops and networking
events that literally had everyone looking up! Yes, all eyes were
skyward as Cirque du Soleil performed their unique acrobatic feats
at the Opening Reception. Tim Lowman elicited a few smiles as he
introduced Cirque as Canada’s top export.
Keynote: Dr. Eric Topol, author of “The Creative Destruction of Medicine”
Dr. Eric Topol delivered a dynamic keynote address, “Connecting
& Collaborating: The Convergence of Life Sciences and High
Tech,” as he spoke of his work to bring a new kind of medicine
into widespread practice, one where physicians
monitor and respond to their patients’
vital signs from anywhere in the world. His
examination regarding the convergence of
pharma, high technology and diagnostics
and its potential to revolutionize healthcare
was not only heard by Annual Meeting
attendees, but is also being heard around
the world through various blogs, podcasts,
magazine articles and interviews, most recently featured on NPR’s
Science Friday. Named the Most Influential Physician Executive in
Health Care by Modern Healthcare and a Rock Star of Science by
GQ magazine, Dr. Topol provided an entertaining, educational and
thought-provoking session that did not disappoint.
He cut right to the chase by showing high-tech gadgets helping
to individualize medical care and allowing physicians to monitor
patient conditions from a remote location. As he displayed the
Zio sleep monitor, Dr. Topol spoke of the importance of sleep in
regards to learning, performance and preventing obesity. He cited
sleeps effects on top athletes, referring to Lebron James who gets
twelve hours of sleep a night!
Dr. Topol continued unveiling other high-tech tools for patients
and doctors:
•AliveCor, which performs and sends an EKG using a smartphone.
•EyeNetra mobile phone attachment that delivers on-demand
eye care by diagnosing certain conditions
•Blood sugar meters that transmit information from a patient’s
“patch” to their doctor through a mobile phone.
Dr. Topol stated that he hasn’t used a stethoscope in more than
two years. Instead, he prefers an ultrasound scanner that fits in his
pockets. Referring to wireless gadgets, smartphones, and the new
immediacy of information, Dr. Topol begs the question: Why do
we need hospitals when everything can be done virtually?
The session broke through the boundaries of traditional medicine,
an area that Dr. Topol is quite familiar with his 14-year
background as chief of cardiovascular medicine for the Cleveland
Clinic and his current position as director of the Scripps Translational
Science Institute. Richard Razgaitis summed up this inspirational
session by stating, “Thank you for bringing our plenary
sessions to a whole new level.”
Read on for capsule reviews by our team of roving reporters.
“How Outcomes of Patent Fights have Changed
the Course of History”
A highlight of the 2012 Annual Business Meeting
was an address by renowned author and
historian Maury Klein, professor Emeritus of History,
University of Rhode Island, who discussed
how the outcomes of patent fights have changed
the course of history. In Mr. Klein’s view, historical
patterns are repetitive in nature, and while it
may feel as though today’s behemoth patent wars
are a new frontier, the fact is that such wars span
the ages beginning with the development of the
patent system itself in the 1600s and continuing
though the advent of embattled technologies such
as the steam engine, the cotton gin, the telephone,
the air machine and others. —Lydia Steck
“Growing the Value of Your Technology Prior
to Licensing, Next-Stage Funding or Next-
Round Financing”
This Life Sciences Sector workshop presented
the application of a proven risk management
approach to growing the value of a technology
portfolio, or venture. The premise of the
framework, which was the first layer of a full
methodology, described a pre-revenue venture,
where the value of the venture is primarily a
function of risk. Most participants were technology
transfer personnel actively involved in
the management of technology spin-offs; a case
scenario provided lively discussion among the
group. —Jackie Csonka-Peeren
Bob Branson (left), Tom Filarski, Eric Topol &
Chuck Neuenschwander
▲
▲
▲
“Convergence in the C
Bringing Innovative Pro
The need for strong, g
is growing according to
Senior Director, Strate
Merck & Co., Inc. and
own consulting firm. L
of convergence” and ad
can serve as a critical t
extend brand equities
zone” into new channe
potential to endure. Pa
how to extend brands
bining to create more
“Russia Joins the WTO - C
Tech Climate Coming”
This Hot Topics Works
Toronto and Sergey Medv
implications for LES memb
Federation recently becom
(August 22, 2012). Russia’s
results in what is called th
respect to foreign investm
Russian government has a
reforms, and these negativ
warranted. Medvedev the
ties, including grants, at Sk
under development. Both
of Russian IP law and prov
8 LES Viewpoints

lair
LES 2012 Annual Meeting Recap • October 14-17, 2012 • Toronto, ON, Canada
“Benches Unleashed: Judicial Views on Fixing the Systems”
Wednesday morning kicked off with an informative
session featuring Honourable Judge Roger Hughes of
the Federal Court of Canada and Honorable Paul Michel,
retired Chief Judge of the United States Court of
Appeals for the Federal Circuit. Brian O'Shaughnessy,
Shareholder at RatnerPrestia, acted as moderator
for this lively session. The discussion spanned a wide
range of topics, including the role of IP in advancing
the economy, the America Invents Act, the way in
which the Courts have interpreted the laws passed by
Congress, and what can be done to promote sound IP
policies. —Brian Frizzell
▲
onsumer Products:
ducts to Market”
lobal brand equities
Susan Levy, former
gy Development for
current founder of her
evy examined the “issues
dressed how licensing
ool to strengthen and
beyond their “comfort
ls that can provide the
rticipants brainstormed
into other areas, combrand
equity.
▲
“Advanced Negotiations - A Walk on the People Side”
In the “Advanced Negotiations: A Walk on the People
Side” workshop, Dr. Robert Fisher emphasized that in
any negotiation, differing perceptions can drive dramatically
different negotiation outcomes. Since individual
and team psychology shape perceptions, they also drive
how choices are made, how decisions are formed and
how we negotiate. Essentially, there are negotiating
behaviors, which can be observed, chosen and changed
to competitive advantage. Fisher introduced TASC-T,
an assessment tool to evaluate and make those choices.
The Advanced Negotiations Workshop was lively and
informative and included seasoned panelists Cheryl Cejka,
Lenny Terry and Sandeep Agarwal. —Robert Fisher
▲
“Is High Tech Crazy? Are We Experiencing a Patent Bubble?”
A panel moderated by Chuck Neuenschwander of IPLC
and comprised of Joff Wild of IAM Magazine, Joe Dillon of
BIO, Dooyong Lee of Acacia Research, and Mike Lasinski
of 284 Partners, discussed whether or not the market
for IP-based transactions is in the midst of an irrational
expansion and overvaluation. Among other topics, the
panel addressed the difficulties inherent in the real-time
detection of market "bubbles," the various indicators of
diligent and rational portfolio evaluation by Rockstar and
Google, the misunderstanding of the IP marketplace by
mainstream media and the wider investment community,
and the risks and opportunities to the IP community in
light of the recent focus on IP-based transactions.
—Chris Schulte
hanges in the Russian IP &
hop, led by Paul Jones of
edev of Moscow, addressed
ers regarding The Russian
ing a member of the WTO
negative perception often
e “Russian discount” with
ent. As Jones discussed, the
continuous track record of
e perceptions are not fully
n described the opportuniolkovo,
a major science park
speakers discussed the state
ided deal tips.
▲
▲
Networking at the Four Seasons Centre for the
Performing Arts
The Annual Meeting was rich with networking opportunities.
On Tuesday evening attendees were awestruck
by the contemporary spaces inside the Four Seasons
Centre. Food and drinks were available on three levels
accessible via glass staircases.
At the Opening Reception, the Cirque du Soleil acrobats
delighted and entertained, as all wondered, “How is
that possible?”
The Tech Fair also provided networking and access to
new technologies and services from a variety of sponsors
and service providers.
November 2012 9

Local Chapter Awards
In celebration of the hard work and dedication of so many volunteers
at the local level, LES (USA & Canada) presented its
Local Chapter Awards during the recent Annual Meeting in
Toronto. Congratulations to the following award-winning chapters:
• Toronto Chapter (Charles Boulakia, Chair):
Excellence in Leadership
• Montreal Chapter (Annie Gauthier, Co-Chair and Natacha Mongeau,
Co-Chair): Small Chapter Award,
Most New Members in 2012
• New York City Chapter (Arnold Burstein, Chair; Viviane Martin,
Co-Chair, Christine T. Fischette, Co-Chair, Barbara A. Sawitsky):
Large Chapter Award, Most New Members in 2012.
• New Jersey Chapter (Linda Webb, Chair, and Lori Waldron, Co-
Chair): Large Chapter Award, Highest Single Event Attendance.
• Silicon Valley Chapter (Damon Matteo, Chair): Most Meetings in
2012, accepted by Craig Smith.
• Houston Chapter (Anne Culotta, Chair): Most Creative Award. ■
Notice from Linda Webb, New Jersey Chapter Chair:
Due to Hurricane Sandy, the LES New Jersey Chapter meeting
scheduled for Oct. 30th had to be cancelled. The topic of “Investing
in Entrepreneurs” will be rescheduled sometime next year. Our next
scheduled meeting in 2012 is Dec. 13 for the annual holiday gathering.
In the meantime, the chapter leadership team wishes everyone a
safe recovery and we hope your hardships will soon be overcome.
Chapter Chair Award winners celebrate, from left,
Linda Webb, Christine Fischette, Barbara Sawitsky and
Annie Gauthier.
Lorraine Fleck
(incoming Chapter
Chair, Toronto) accepts
the Excellence
in Leadership Award
from Hilton Sue.
Alaya Bettaieb
Champions IP for
Rebuilding Tunisia’s
Economy
By Linda Corcoran
What does it take to rebuild a
country? Alaya Bettaieb knows
that rebuilding the economy in
Tunisia presents plenty of challenges and
opportunities for international intellectual
property partnerships. Speaking at the
Annual Meeting, Bettaieb introduced the
situation in post-revolution Tunisia and
the surrounding area, describing how the
Michael Martin introduces Alaya Bettaieb
at the Annual Meeting in Toronto.
10 LES Viewpoints
ensuing Democratic process has created a
freedom of expression and a freedom of
entrepreneurship.
Mr. Bettaieb is the Secretary of State to
the Ministry of Investment and International
Cooperation of Tunisia and is an LESI
Certified Licensing Practitioner (CLP). A
successful Venture Capitalist, Bettaieb has
provided first seed and corporate venture
funds in Tunisia targeting high value added
technology projects in Northern Africa. In
2005, he gained the trust of the U.S. government
to lead a North Africa Innovation
program launched to value technology in
innovative SMIs in the region. He directed
UAE, an Academic Technology Transfer
program assessing the commercialization
of research results in Arab Universities and
created 10 Technology Transfer Offices
in 10 Arab countries, an ambitious project
badly affected by the world financial
crisis in 2008. In 2010, he moved to Saudi
Arabia to coach a team from KAU in the
validation of research results in treating
the reject of brackish water desalination
plants crowned by the creation of a startup
commercializing the result. In August
2011, he came back to Tunisia to set up a
Technology Fund targeting the acquisition
of clean technologies for Northern African
markets.
“There is new hope in building a new
country,” says Bettaieb. “Today Tunisia is
writing a new constitution and new legal
reforms around issues such as IP.” In his
presentation, “The Role of IP in Rebuilding
Economies Following the Arab Spring,” he
spoke of Tunisia’s technology upgrading
as “food” for business activities from one
country to another. The luncheon presentation
was an intellectual opportunity for
participants to tie together current issues
and gain a realistic image of North Africa,
how they are using IP, and where international
assistance is needed.
Current challenges facing Tunisia include
more than 200,000 unemployed university
graduates and the disparity of wealth by
regions. The transition to build a better
model for the country’s economy is driven
by technology, which Bettaieb says, “brings
both challenges and opportunities.”
In his presentation, Bettaieb emphasized
the need for international partnerships
as well as crucial policymaking, which
would allow investors to feel safe and
comfortable.
In a country crushed under a 20+ year
dictatorship, post-revolution freedoms are
opening the door to initiatives that have
long been forbidden. The country is starting
to brim with entrepreneurs, who need
the encouragement and guidance of IP
professionals. “We cannot do it alone,” says
Bettaieb. “There is a need for expertise.” ■

Crowdsourcing Session Examines Commercial Space
Strategies And Trade-Offs While Breaking New Ground
By Linda Corcoran
Texts and tweets infused the conversation
as LES (USA & Canada) Annual
Meeting goers in Toronto broke new
ground in a session that invited participants
to augment the conversation using their
Blackberries, iPhones, and the like. The topic,
“Carving Out Your Commercial Space—
Strategies and Trade-Offs,” was centralized
around three big questions and looked to the
crowd for unique perspectives on alternative
strategies that ensure their companies’
freedom to successfully carve out space in
the marketplace.
Tim Lowman acted as the “Oracle” (the
voice of texts and tweets), and provided the
session overview as Kathleen Denis, Associate
VP, Office of Technology Transfer
at Rockefeller University, and Richard
Razgaitis, Senior Advisor for Charles River
Associates, led the discussion from the stage.
Question #1: To search or not to search?
Denis posed the first big question: Company
cultures used to grow organically, but now
that is changing. Most pharma companies
have scouts visiting other small companies
looking for technology to bring home. Many
other industries have not adopted those strategies;
instead, they go out and conquer. Should
these other companies go out and search?
The conversation quickly centered on
sourcing products in DICE (Digital Information
Computing Electronics) as an audience
member commented that there were “tens of
thousands” of open innovation products in
this space and noting their longer than usual
timeline in bringing technology to market.
A question was entertained regarding a
parallel system being set up in other social
media in order to ascertain who is out searching
and who is not. Razgaitis interjected that
Kodak, which is now in bankruptcy, may
have had a different fate if they had been
scouting outside their walls. “Could DICE
take some advice from that?” he asked.
A member of the audience commented that
people in the DICE space weren’t even aware
of licensing practices until they came to LES
and heard various presentations. Another
audience member’s comments stated, “If I
want to develop a drug I know it is going
to cost $10 million and take 10 years. You
don’t need to wait for that in social media or
Internet areas.”
A poignant tweet came in: “If you want to
find the next big thing,
don’t go to a university.
Go to Berkeley
coffee shops and talk
to students.”
Some distinctions
were made regarding
DICE looking for
opportunities that are
fused to technology
that is already in place
versus Life Sciences
technology, which is
more stand-alone.
Further comments
on this key question
included considering
changing a company
culture to be more
open to looking for
opportunities as well
as creating a doorway
at LES meetings by
introducing yourself
to people who may hold a strategic advantage
for your company.
Question #2: Is there value in
IP collaborations?
A second key question was posed by
Razgaitis: Is the participation in IP collaborations—for
the purpose of freedom of action,
or new business opportunities, or both—an
important strategic opportunity for Life
Science companies? If so, what research or
communications are most attractive for such
collaborations and what are the associated
high-importance IP/Licensing issues?
An audience member quickly jumped into
the conversation citing the chemical space’s
use of upstream opportunities as an example
of well-managed collaborations. It was noted
that Life Science would have to change its
culture to have a similar positive experience.
Denis mentioned that several universities and
pharma collaborations are already doing so.
Concern for NPEs (Non-Practicing Entities)
participation in collaborations was
voiced, mentioning that NPEs might gain
access to patents, but collaborations might
head off the purchase by NPEs. Other areas
of collaboration were recalled, including 3M
Ventures, plastics and the auto industry, and
the DICE industry.
Kathleen Denis (left) and Richard Razgaitis lead the Crowdsourcing
session in Toronto.
Question #3: Advice for First To File?
The final question was in regard to the
America Invents Acts: What can our Canadian
and other non-U.S. colleagues tell
us about strategy and tactics under First
To File? With a university exception to the
prior user rights defense, will companies
rethink their filing strategy?
An attorney in the crowd submitted,
“Under the America Invents Act, everyone
files provisional applications. The
grace period has eviscerated the one-year
waiting period.”
Others stated that there should be a race
to the patent office with people getting
their provisional patents on file and that
there is a need to file before inventions
are mature. A Canadian attorney stated,
“Many are looking globally and examples
of First to Invent are available globally. I
don’t think this will change too many of
my clients’ strategies.”
Different industries were examined
throughout the conversation. It was mentioned
that universities would be impacted
on smaller projects with upfront expenses.
DICE industries will be impacted by First
To File and will be taken aback by their
longer time frames for development. ■
November 2012 11

Marie Escobar:
Front and Center for LES Education
By Linda Corcoran
Marie Escobar, adding value through
quality programming
The Annual Meeting in
Q: Toronto proved to be quite a
success. What was your role at the
meeting?
Marie: If you’ve ever attended
A: an LES (USA & Canada) annual
or seasonal meeting, you may
have noticed staff members from LES
Headquarters working from morning
to night to ensure that every attendee
walks away with a high value, high
quality experience. In Toronto, I was
personally responsible for providing
Sunday’s educational programming,
which was comprised of six workshops
focused on CLP (Certified Licensing
Professional) domains. I also coordinated
the day long Licensing Basics
Course. I also worked with our Annual
Meeting speakers and managed our
Virtual Annual Meeting offering.
What do you enjoy most about
Q: attending annual and seasonal
meetings?
A:
Marie: The main benefit of
meetings and what I personally
enjoy the most is interacting with
members. I cultivate so many relationships
throughout the year without ever
meeting the Individuals. The Annual
Meeting is a great time to put a face
and a name with the voice and to actually
develop those relationships.
Most of the time you are
Q: working out of the LES (USA
& Canada) headquarters in Alexandria,
Virginia. What are your day-today
responsibilities?
Marie: LES (USA & Canada)
A:
Headquarters is the engine that
supports the day-to-day operations of
the Society. My responsibilities include
overseeing all professional development
initiatives, including education
programs, from Basics to Best Practices,
LES University, webinars and new
virtual options, as well as working with
meetings teams on program design.
What is the most interesting
Q: aspect of your job?
Marie: LES is interesting just
A:
because of the diversity of the
membership. Not only am I able to
assist members through association
management, but I am also learning
efficient business practices and tools
from the members themselves. On a
personal level, the skill sets that the
members bring have made me better at
my own job.
What are the challenges that
Q: you face in your role with LES?
Marie: In the current business
A:
climate, it is important to balance
the traditional values of membership
with new learning devices and principals.
Tightened travel budgets make it
more difficult for members to come out
to educational meetings and programs.
In turn, we’ve begun to offer hybrid
meetings where plenary sessions are
An interview with Marie Escobar, LES Education
and Program Content Manager.
broadcast to members. The challenge is
to bring content to people who cannot
attend meetings and to balance that
with the value of networking, which
makes membership in LES unique.
What are some of your goals
Q: for education and programming
in the coming year?
Marie: My main goals are to offer
more hybrid meetings and to
A:
make education more available at the
Chapter level.
What past experiences have
Q: prepared you for your role
with LES?
A:
Marie: Prior to joining LES,
I was the Foundation Director
for the American Chiropractic Association
(ACA). Through my tenure, I
established certification programs and
supplemented their education programs
with resources and learning materials.
What was it like to work with
Q: chiropractors?
Marie: The benefits were great.
A:
The chiropractors used to offer
“free” stress-reducing adjustments at
ACA annual meetings!
How do you spend your time
Q: when you are not working in
the LES office or on-the-road at an
LES meeting?
A:
Marie: I enjoy spending downtime
with my husband at our
home in Northwest D.C. I am also a
part-time student at American University
and will be graduating in May
with an MBA in Emerging Markets. ■
Rates, continued from Page 3
A total of 120 completed surveys were incorporated into
the final Global BioPharma Survey Report with almost half
of the reported deals from outside North America. Of those
who responded, 31% were from pharmaceutical companies,
22% were from biotech companies, 9% were from academic
institutions, 6% were from government, and 32% were
from other organizations.
The surveys were designed by committees of experienced LES
members within the Life Sciences Sector who worked alongside an
independent team from Veris Consulting, LLC, on design, dissemination,
data collection and analysis and ensuring confidentiality.
The final Global BioPharma Royalty Rates and Deal Terms
Survey Report will be made available online exclusively to LES
members worldwide in November. For more information, visit
www.lesusacanada.org. ■
12 LES Viewpoints

SAVE THE DATE
FOR 2013 LES
MEETINGS
© Copyright Greater Phoenix CVB
IP100 Executive Forum
February 11–12
Phoenix, AZ
Spring Meeting
May 14–16
Seattle, WA
© Copyright Tim Thompson
Annual Meeting
September 22–25
Philadelphia, PA
Photo by B. Krist for GPTMC
More details coming soon. Check in at www.LESUSACanada.org
November 2012 13

Acceptance to membership
in LES (USA &
Canada) will be effective
30 days from the date
of publication herein
unless, in the meantime,
notice has been given to
the Membership Committee
of an objection
to the membership of a
listed applicant.
Andrew Adler
Citrin Cooperman
Jeffrey Adams
Ray Adams
MOSAID
Douglas Adams
The City Univ. of New York
Franklin Akomeah
Melissa Alcorn
Oklahoma Medical
Research Foundation
Edward Allen
Lockheed Martin Corp.
Richard Allison
Hudson Bay Capital
Management LP
Uzi Aloush
SynPat - Syndicated Patent
Acquisitions Corp.
James Alva
Tech Futures Group
Dmitriy Andreyev
Flagship IP, P.C.
Robert Andris
Ropers Majeski, Kohn &
Bentley
Benjamin Anger
Knobbe, Martens, Olson
& Bear, LLP
Steven Arnold
Micron Technology, Inc.
Tony Asseiro
British Columbia Institute
of Technology
Mark Austin
Chandler Reed, LLC
Jessica Avery
New Hampshire Ball
Bearings, Inc.
Michael Banco
S.C. Johnson & Son, Inc.
Steve Banet
UCB Inc
Audrey Banks
Henry M Jackson
Foundation
Luke Barbin
Cardinal Intellectual
Property, Inc.
Tom Barnett
Masco Corporation
Paul Barone
Inspirion Pharmaceuticals
14 LES Viewpoints
LES (USA & Canada) New Members
Due to space constraints, new member addresses can be found on the LES Web site, www.lesusacanada.org
Rishi Batra
Innovate Calgary
Laura Becker
Procter & Gamble
Matthew Behan
KPMG LLP
Brinda Bellur
Laxminarayan
David Bennett
Western Michigan
University
William Berg
Novartis Pharmaceuticals
Elana Bertram
Michaud-Kinney Group,
LLP
Samik Bhattacharyya
VICIS Consulting Group
LLC
Michael Binz
Deloitte Financial Advisory
Services LLP
Anna Bley
Innovation Accelerator
Mark Blomquist
Landmark Financial
Corporation
Richard Boudreault
Veronique Bougie
Gestion Univalor, LP
Charles Boulakia
Ridout & Maybee LLP
Francois Boulianne
Besner Attorneys &
Business Advisors
Johan Brag
INNOVA LAW, LLC
Tony Brazzale
Melanovus Oncology
Garold Breit
University of Louisiana
Odd Bres
University of Manitoba
Ryan Buckmaster
UW Center for Commercialization
Danielle Bush
Chitiz Pathak LLP
Steven Cahn
Cahn Litigation Services
Pamela Carey-Mackenzie
P&G
Sean Carroll
Robert Carruthers
Innovate Calgary
Meredith Carter
Rembrandt IP Management,
LLC
Ping Cheng
Merck Sharp & Dohme
Corp.
Dan Chicoine
Nuvo Research Inc.
Elvina Chow
Forrest Chumley
Heartland Plant Innovations,
Inc.
Marie Clark
Cosmederm Bioscience,
Inc.
Gavin Clarkson
University of Houston
Law Center
Mattie Clay
Richard Conroy
Navigant Economics
Jeff Cope
RTI International
Rick Covington
Halliburton
Regina Culbert
Merchant & Gould
Brian Cummings
OSU Technology
Commercialization &
Knowledge Transfer
Skip Cynar
University of California
- San Diego
Paul Cyr
The University of British
Columbia
Lane Czekala
That Corporation
Brian Darville
Brocadiant Legal PLLC
Debarshi Das
Intellectual Ventures
Janice Davis
Bracewell & Giuliani
LLP
Anton Dawson
Virginia Commonwealth
University
Steve De Brabandere
University of Guelph
Paul Debbie
Boyce Thompson Institute
for Plant Research,
Inc.
Mark DeLong
EMD Serono
Yasmin Dennig
Sandia National Labs
Richard Deschenes
INO
Lisa Desjardins
Esperanza Diaz
Christine Dixon Thiesing
Charles Donohoe
Charles R. Donohe, P.C.
Kristine Dorward
Aptalis
Glenn Dourado
Ligand Pharmaceuticals
Inc.
Tim Doyle
Christopher Ekren
Sony Electronics Inc.
Gerard Eldering
Technology, Patents &
Licensing
Patrick Ellisen
Greenberg Traurig LLP
Priscille Ernotte
Institut National de la
Recherche Scientifique
Jerome Etwaroo
University of Victoria
Paul Eynott
The University of
Arizona
Debra Fin
Dow Corning Corp.
Jeffrey Finn
Sidley Austin LLP
Robert Fisher
Fisher Leadership
Strategy Execution
Christopher Flores
UVic Industry Partnerships
Brian Foley
NeoStrata
Norby Foss
CBI
Tom Foust
National Renewable
Energy Laboratory
Gregory Frank
XBiotech USA, Inc.
Keith Fredlake
Roberts Mlotkowski
Safran & Cole P.C.
Adam Fromm
Cardinal Intellectual
Property
Camelia Galos
Pratt & Whitney
Jane Garrity
NUtech Ventures
Carl Genberg
N8 Medical
Jason Ghie
IP Research Group
Jon Gibbs
Lowndes, Drosdick,
Doster, Kantor & Reed,
P.A.
Sharon Gibson
Visa, Inc.
Glenna Gilbert
Larkin Hoffman Daly &
Lindgren Ltd.
Siok Goh
MOSAID Technologies
Inc
Joel Goldman
SIPCO, LLC
Ed Gomez
Furnace Brook LLC
Iranzu Gonzalez
Digna Biotech L.L.C
Robert Gould
Husch Blackwell LLP
Carol Greve-Philips
Pronota NV
Francisco Guerra
License My Product
Carl Gulbrandsen
Wisconsin Alumni Research
Foundation
Michael Gulker
TPR International
Mengjuan Guo
University of Lethbridge
Charanjeet Guron
Tina Ha
Benaroya Research
Institute
Attila Hajdu
GlaxoSmithKline
Cory Hallam
The University of Texas
at San Antonio
John Han
Ericsson Inc.
Josh Hartmann
Gina Haschke
Haschke Law PLLC
Dennis Haszko
LettersPatent.com
Christie Hatges
DRI Capital
James Heitner
Ripple Management, Inc.
Meg Helms
Morgan Wallace Associates,
LLC
Lisa Herron-Olson
Syntiron
Chad Hilyard
Rockstar Consortium
US LP
David Hobson
University of Guelph
Tom Hochstatter
Fluid Innovation
James Holcombe
Rockwell Collins, Inc.
David Huffaker
Intellectual Ventures
Ted Ira
Davita
Amit Jhas
MaRS Innovation
Bozhena Jhas
University of Toronto
Steven John
Major, Lindsey & Africa
Gary Johnson
Perception Partners, Inc.
Frank Jones
Whiteford, Taylor &
Preston LLP
Michael Jones
Pepper Hamilton LLP
Heajin Jung
Heajin Jung Law Firm,
PLLC
Kimberly Justice
Deloitte Financial Advisory
Services LLP
Jeewan Jyot
NUtech Ventures
Donald Kakuda
UCSD Technology
Transfer Office
Matthew Kalnik
Nabi Biopharmaceuticals
Maki Kanayama
Kanayama Law Office
Steven Karski
Efrat Kasznik
Foresight Valuation
Group LLC
Anant Kataria
Sagacious Research
Wendy Kearns
Snodgrass & Kearns,
PLLC
Mike Keenan
WI-LAN Inc.
Mark Keith
IEC & Associates
Brian Kelly
Cornell Center for
Technology Enterprise &
Commercialization
Matthew Kelly
CME Group Inc.
Brian Kemp
Boeing Intellectual Property
Licensing Co.
Nicoletta Kennedy
Roberts Mlotkowski
Safran & Cole
Ahsen Khan
Intermountain Healthcare
(Intermountain
Invention Management
LLC)
Heather Khassian
Bracewell & Giuliani
Gaby Khouri
RPX Corporation

Jin Kim
IP Navigation Group
Chang Kim
CJ America, Inc.
Don Kirksey
Clearside Biomedical
Kevin Kleespies
The Clorox Company
Bruce Koch
Schmidt LLC
Christopher Koch
Techquity Capital Management
Alon Konchitsky
http://ip-consult.net/
Pieter Kooiman
AstraZeneca Canada
Inc.
Ann-Marie Koss
Invotex Group
Ronnie Koss
IdeaPoint
Brad Krawczyk
Apotex
Marcus Kuizenga
James Hardie
Jason Kulick
Indiana Integrated Circuits,
LLC
Winston Lam
Caris Life Sciences
Courtney Lambert
Emergent Technologies,
Inc
Jessica Landacre
Intellectual Property
Owners Association
Gail Langer
St Teresa Medical Inc.
Sun Lee
Heajin Jung Law Firm,
PLLC
James Lee
Novo Nordisk Canada
John Leja
Polsinelli Shughart PC
Mauro Leos
Illinois Institute of
Technology
Per Lindell
Novadigm Consulting
Group
Jeffrey Lindgren
Vasquez Benisek &
Lindgren LLP
Martin Lindsay
Bowers & Wilkins
Brandon Lloyd
Duff & Phelps LLC
Ling Loerchner
University of Waterloo
- WatCo
Due to space constraints, new member addresses can be found on the LES Web site, www.lesusacanada.org
Mark Lopes
TSC
John Lopez
Axiom Global
Ethan Lovell
Janus
Drew Lowery
Global Prior Art
Bette Lyons
Saskatchewan Research
Council
Anastasia Magoulias
Life Technologies Corporation
Mahmoud Mahmoudian
Ferring Pharmaceuticals
Barry Markowsky
Convergent Healthcare
Jim Martin
SmartAnalyst, Inc.
Christine Mayer
Vaxlnnate Corporation
Alan McClure
Texas Instruments Incorporated
David McClure
Michael McGovern
Matson Driscoll &
Damico
Sean McIntyre
Robert McSorley
Ocean Tomo
Ian Mehr
Kowa Research Institute
Douglas Meier
Finnegan Henderson
Farabow Garrett & Dunner,
LLP
Sheila Mikhail
Life Sciences Law PLLC
Jonathan Minnaert
Teva Pharmaceutical
Miguel Mireles
Xolve, Inc.
Alex Modelski
Ater Wynne LLP
Katherine Moldave
AlcheraBio
Beverley Moore
Borden Ladner Gervais
LLP
Richard Moses
Pachira IP Inc.
Chris Murphy
UBM TechInsights
Richard Murphy
Brian Musa
Pilar Najarro
Digna Biotech L.L.C
LES (USA & Canada) New Members
Thomas Nealssohn
Masco Corporation
Research & Development
Joseph Nguyen
Intellectual Ventures
Nam Nguyen
Quick-Med Technologies,
Inc.
Michelle O’Brien
O’Brien Jones, PLLC
Koki Ohashi
Kissei America
Ellie Okada
Boston Cancer Policy
Institute, Inc
Lowell Oster
AppliCote Associates,
LLC
Veronique Page
Mosaid Technologies Inc.
Suchismita Pahi
Ricardo Palacios
Digna Biotech L.L.C
David Paratore
The NanoSteel
Company Inc.
Jae Park
Kile Park Goekjian
Reed & McManus PLLC
Kaushik Patel
University of Toronto
Mihir Patel
Allied Security Trust
Marc Perron
Alizem Inc.
Mike Pisterzi
PanOptis IP
Robert Piston
Francis Plati
Sughrue Mion PLLC
Jeff Pootoolal
DRI Capital
Jill Powlick
BioFire Diagnostics, Inc.
Joanna Preston
TEC Edmonton
Christopher Price
LifeScience Consultancy
Anthony Provitola
Anthony I. Provitola,
P.A.
Richard Purcell
DNA Healthlink, Inc.
Samir Raiyani
Dolcera
Ramesh Rajaduray
Stratford Managers
Vicki Randall
The Clorox Company
Francois Ravenelle
Oncozyme Pharma Inc.
Frank Razavi
Purdue Research Foundation,
OTC
Scott Rediker
Merrill Corporation
Bryan Repetto
Applied Research Works
David Richards
N8 Medical, Inc.
Sean Ricks
Vivint, Inc.
Alan Ritchie
James Roberts
Rembrandt Virginia
Management
Isabelle Robitaille
Norton Rose Canada
LLP
Michael Ronning
Purdue Pharma, LP
Stuart Rosove
Irdeto
Christopher Roth
Shire Pharmaceuticals
Sam Rothstein
University of Pittsburgh
Steven Rowan
Seabreeze Ltd.
Israel Rozen
Broad Institute of Harvard
& MIT
Adam Rubenstein
Andrea Rush
Heenan Blaikie LLP
Kashinath Sadalapure
Phyton Biotech LLC
Rade Sajic
Andrews Robichaud
Intellectual Property
Lawyers & Business
Law
David Sasso
Intellectual Ventures
LLC
George Sawyer
Evalueserve
Scott Scaramastro
Agilent Technologies,
Inc.
David Schatz
WiTricity Corporation
Thorsten Schmidt
Schmidt LLC
Jennifer Schrader
Counterpoint Systems, Inc
Orit Segev
Genome BC
Madhu Sharma
Univ. of California, Davis
Bradley Shaw
Michigan State University
Anthony Shull
Sunovion Pharmaceuticals
Leticia Silva
Tyler Sims
Sims Strategies LLC
Raja Singh
Innovate Calgary
Scott Smedresman
SorinRand LLP
Linda Smibert
Kowa Pharmaceuticals
America, Inc.
Andrea Sotak
DRI Capital Inc.
Mark Stallion
Husch Blackwell LLP
Judith Stein
Vaccine Research Center/NIAID/NIH
Justin Stewart
Micron Technology, Inc.
Carrie Stroup
Summersby Intellectual
Property Consulting
Suresh Sunderrajan
United Technologies
Corporation
Michael Swan
Global Royalty Audits,
Inc.
Lawrence Tedesco
DRC, LLC;
U.S. Ethernet Innovations,
LLC
Jason Teller
Intellectual Ventures
Dan Templeton
Brooks Kushman PC
Jon Tepp
Laurits R. Christensen
Associates, Inc.
Ray Throckmorton
R3T Consulting Group,
LLC
Michael Thumm
Pachira IP Inc.
Mike Tobin
Parker Poe Adams &
Bernstein LLP
David Tollen
Tech Contracts Chalkboard
Thomas Tolpin
Tolpin & Partners, PC
Peter Tong
IP Ventures, Inc.
Elo Tulving-Blais
Tulving-Blais International
& Tech Law
Antonio Turco
Blake, Cassels & Graydon
LLP
Nathan Valverde
Sanofi- Aventis, Franklin
Pierce Center for
Intellectual Property
Vikram Venkataramani
Global Licensing Audit
Services, Inc.
Annemarie Vicere
Osha Liang LLP
Lester Vincent
Blakely Sokoloff Taylor
Zafman LLP
Eve Wahn
WahnLaw
Rob Warner
FTI Consulting
Leland Webster
Tetraphase Pharmaceuticals,
Inc.
Peter Weinstein
One3 IP Management
Annette Weissbach
Roche
James Weyhenmeyer
Georgia State University
GSU
Renee Whynes
Energizer Personal
Care
Timothy Willis
UNH-ORPC
Hugh Wilson
Russell Wilson
Novavax, Inc.
James Windsor
Emergent Technologies,
Inc.
Jeffrey Witcher
AstraZeneca Pharmaceuticals
LP
Joe Wyse
Wyse Innovations
Xin Xu
Princeton University
David Zembower
Rehabilitation Institute
of Chicago
Adrianna Zhang
TSRI
Chunyu Zheng
Jingyu Zhou
Comcast
Christopher Ziegler
Ken Zinda
Inspherion
November 2012 15

ADDRESS SERVICE REQUESTED
PRSRT STD
U.S. POSTAGE
PAID
ZIP CODE 44101
PERMIT NO. 1501
LESEvents
2012 LES Annual Meeting Committee
2013
January 21-22
Global Technology Impact
Forum (GTIF)
Geneva, Switzerland
February 11-12
IP100 Executive Forum
Arizona Biltmore
Phoenix, Arizona
March 14-16
LES Australia and New Zealand
Annual Conference (LES ANZ)
Brisbane, Australia
April 5-7
LES International Management &
Delegates' Meeting (IMDM)
Rio de Janerio, Brazil
April 7-10
LESI Annual Conference
Windsor Atlantica Hotel
Rio de Janeiro, Brazil
May 14-16
LES (USA & Canada)
Spring Meeting, Keynote Speaker
David Kappos, Director of USPTO
W Hotel
Seattle, Washington
June 23–25
LES International
Pan-European Conference
Davos, Switzerland
September 22-25
LES 2013 Annual Meeting
Philadelphia Marriott Downtown
2014
May 21-23
LES International Annual
Conference
Moscow, Russia
October 5-8
LES 2014 Annual Meeting
San Francisco, California
February 11-12, 2013
Arizona Biltmore
Phoenix, Arizona
The IP100 Executive Forum is a unique
and exclusive gathering of senior
executives charged with the IP decision-making
responsibilities within their organizations.
The IP100 focuses on strategic
issues related to IP business, including IP
valuation, best practices in deal structure, IP
strategy and organizational alignment.
Held annually, the event explores the
business dynamics of IP and organizational
strategy through panel and small, facilitated
Special thanks to the
LES 2012 Annual Meeting
Committee: Tim
Lowman (front left),
Gary Fedorochko, Tom
Filarski; (back left) Hilton
Sue, Mitch Charness,
Bob Held, Chuck Neuenschwander
and (top)
Carolyn Rockafellow.
group discussions, where the focus is on
peer-to-peer interactions, thought-provoking
engagement and valuable takeaways
to implement and integrate immediately
into your organization. Attendance
is limited to experienced, managementlevel
professionals from various types of
organizations of all sizes and industries.
Visit www.IP100.org for more information
and to request an invitation. Space is
limited to 100. ■
Printed on Recycled Paper